Breaking News

ORTHO Optix Reader Receives CE Mark and Available in Countries That Accept the CE Mark

"The ORTHO Optix Reader allows transfusion medicine labs with smaller testing volumes the same high-quality, consistent results demonstrated from the award-winning, fully automated ORTHO VISION Analyzer," said Bob Stowers, Ortho's head of transfusion medicine product portfolio.

Medtronic and the Medtronic Foundation Announce Additional and Generous $3.8 Mil Commitment to Protect and Support Healthcare Workers During COVID-19

"As the coronavirus pandemic surges around the world and in our own backyard, healthcare, food assistance, and mental health pressures are at all-time highs; it is crucial for us to deliver support quickly to counteract the disproportionate effect the virus has on underserved, marginalized communities," said Paurvi Bhatt, president of the Medtronic Foundation. "In this season of giving, we are also turning our gratitude into action by coming together with our partners to support these issues and the brave frontline health workers who are in need of services themselves."

Canon Medical at RSNA 2020: Virtual Showcases Aquilion ONE / PRISM Edition, AUTOStroke Solution, Compressed SPEEDER

Canon Medical at RSNA 2020 Breaking News: To meet the growing cardiovascular needs of healthcare providers today, Canon Medical Systems USA, Inc. is breaking ground once again with the introduction of Deep Learning Spectral CT for cardiovascular imaging and more!

3M and Rad AI Team Up to Offer Rad AI’s Advanced Technology for Generating Customized Radiology Reporting

November 30, 2020 3M and Rad AI goals: “Rad AI and 3M share a common goal of helping radiology teams become stronger and more resilient...

Samsung Introduces Its Latest Radiology Innovations at RSNA 2020

Samsung to highlight its medical imaging portfolio with its latest radiology innovations in ultrasound, digital radiography and mobile computed tomography.

FDA Posts Additional Postmarket Information for Essure

Essure: The following quote is attributed to Benjamin Fisher, Ph.D., director of the Reproductive, Gastro-Renal, Urological, General Hospital Device and Human Factors Office in the Center for Devices and Radiological Health  

“The FDA continues to take concerns about Essure very seriously. Consistent with our previous updates, we are committed to continuing our postmarket evaluation of this device and providing updated information periodically. In that spirit, today, the FDA posted the first spreadsheet of adverse event reports pertaining to information received from certain social media sources, in relation to ongoing litigation about this device.

As this information is based on social media posts, these reports may reference information already reported to the FDA and do not necessarily represent new adverse events. The limited information provided in the reports prevents the ability to draw any conclusions as to whether the device, or its removal, caused or contributed to any of the events in the reports. The FDA reviewed the first spreadsheet of reportable events, and the nature and severity of the reports remain consistent with Medical Device Reports (MDRs) received for Essure since 2017.

The FDA received these reports from Bayer, who manufactured and sold this device until 2018. Bayer will continue to provide monthly spreadsheets of reports through April 2021, as well as provide quarterly and final analysis reports evaluating the events reported and how the information compares to other MDRs for Essure. We will continue to ensure that all reportable adverse events identified from this information are submitted to the FDA and made publicly available.”

Additional Information:

  • On April 24, 2020, the FDA granted, in part, Bayer’s request for a variance from some medical device reporting requirements subject to the conditions outlined in a letter issued to Bayer. The variance is limited to MDR-reportable events for Essure that Bayer is, or becomes aware of, from information received November 2016 through November 2020 in connection with litigation regarding Essure and that originated from certain social media information.
  • Although Essure is no longer available for implantation in the U.S., the FDA remains committed to evaluating long-term safety information in women who have received the device, including data from an FDA-required postmarket surveillance study, sometimes referred to as the 522 study.
  • From 2017 to 2019, the majority of MDRs received from Essure were related to potential device removal, as were the majority of reports in the spreadsheet posted today. The FDA expects to have more real-world data from the 522 study about Essure removal, including better information on the reasons for removal and follow-up of patients after removal to assess outcomes. On July 8, 2020, the FDA provided interim results from the 522 study on the Essure 522 webpage.
  • The link to the data file for the first spreadsheet of reportable events is available on the FDA’s “Problems Reported with Essure” webpage. We will post future spreadsheets on this same webpage after the information is received from Bayer and reviewed by the FDA. Bayer submitted a summary of the information in the first spreadsheet through FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.
  • Over the last several years, the FDA has taken a number of actions to monitor the safety of Essure. The agency regularly updates the public about these actions and remains committed to sharing new information as it becomes available.

Additional Resources:

Latest Posts

ORTHO Optix Reader Receives CE Mark and Available in Countries That Accept the CE Mark

"The ORTHO Optix Reader allows transfusion medicine labs with smaller testing volumes the same high-quality, consistent results demonstrated from the award-winning, fully automated ORTHO VISION Analyzer," said Bob Stowers, Ortho's head of transfusion medicine product portfolio.

Medtronic and the Medtronic Foundation Announce Additional and Generous $3.8 Mil Commitment to Protect and Support Healthcare Workers During COVID-19

"As the coronavirus pandemic surges around the world and in our own backyard, healthcare, food assistance, and mental health pressures are at all-time highs; it is crucial for us to deliver support quickly to counteract the disproportionate effect the virus has on underserved, marginalized communities," said Paurvi Bhatt, president of the Medtronic Foundation. "In this season of giving, we are also turning our gratitude into action by coming together with our partners to support these issues and the brave frontline health workers who are in need of services themselves."

Canon Medical at RSNA 2020: Virtual Showcases Aquilion ONE / PRISM Edition, AUTOStroke Solution, Compressed SPEEDER

Canon Medical at RSNA 2020 Breaking News: To meet the growing cardiovascular needs of healthcare providers today, Canon Medical Systems USA, Inc. is breaking ground once again with the introduction of Deep Learning Spectral CT for cardiovascular imaging and more!

iHeartMedia Los Angeles’ KOST 103.5 to Join Children’s Hospital Los Angeles for Fifth Annual Giving Tuesday Fundraising Event

Starting with The Ellen K Morning Show, nationally syndicated on 40 stations, KOST 103.5 will dedicate 12 hours of programming to Giving Tuesday and highlight the world-class pediatric medical care that Children’s Hospital Los Angeles provides by featuring interviews with patient families, hospital leaders, celebrity supporters and sponsoring partners.

Don't Miss

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials. 

Stoke Therapeutics Announces Proposed Public Offering

November 18, 2020 Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein...